IL227782A - Crystalline forms and processes for making cannabinoid receptor modulators - Google Patents

Crystalline forms and processes for making cannabinoid receptor modulators

Info

Publication number
IL227782A
IL227782A IL227782A IL22778213A IL227782A IL 227782 A IL227782 A IL 227782A IL 227782 A IL227782 A IL 227782A IL 22778213 A IL22778213 A IL 22778213A IL 227782 A IL227782 A IL 227782A
Authority
IL
Israel
Prior art keywords
processes
preparation
crystalline forms
receptor modulators
cannabinoid receptor
Prior art date
Application number
IL227782A
Other languages
English (en)
Hebrew (he)
Other versions
IL227782A0 (en
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL227782A0 publication Critical patent/IL227782A0/en
Publication of IL227782A publication Critical patent/IL227782A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL227782A 2011-02-25 2013-08-04 Crystalline forms and processes for making cannabinoid receptor modulators IL227782A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (2)

Publication Number Publication Date
IL227782A0 IL227782A0 (en) 2013-09-30
IL227782A true IL227782A (en) 2017-02-28

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227782A IL227782A (en) 2011-02-25 2013-08-04 Crystalline forms and processes for making cannabinoid receptor modulators

Country Status (20)

Country Link
US (4) US9458136B2 (OSRAM)
EP (3) EP3395812B8 (OSRAM)
JP (1) JP5945554B2 (OSRAM)
KR (1) KR102036932B1 (OSRAM)
CN (1) CN103608343B (OSRAM)
AU (1) AU2012222146B2 (OSRAM)
BR (1) BR112013021549B1 (OSRAM)
CA (1) CA2827057C (OSRAM)
CL (1) CL2013002436A1 (OSRAM)
CO (1) CO6852066A2 (OSRAM)
DK (1) DK3395812T3 (OSRAM)
EA (1) EA035989B1 (OSRAM)
ES (1) ES2932441T3 (OSRAM)
IL (1) IL227782A (OSRAM)
MX (1) MX346533B (OSRAM)
MY (1) MY165767A (OSRAM)
PH (1) PH12013501726A1 (OSRAM)
SG (1) SG192817A1 (OSRAM)
WO (1) WO2012116276A1 (OSRAM)
ZA (1) ZA201306402B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200008045A (ko) 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX346533B (es) * 2011-02-25 2017-03-14 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CN109310673A (zh) * 2016-04-10 2019-02-05 艾尼纳制药公司 用选择性cb2受体激动剂治疗的方法
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
EP3621619B1 (en) * 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
EP1461027A4 (en) 2001-12-07 2005-09-07 Univ Virginia Commonwealth TREATMENT OF NEOPLASIA
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
NZ580387A (en) 2004-07-12 2011-06-30 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体,含有该配体的药物组合物及其制备方法
PL1902034T3 (pl) * 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
ATE459352T1 (de) 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2120938A4 (en) 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
WO2008114619A1 (ja) 2007-03-16 2008-09-25 Kyocera Corporation 誘電体磁器およびコンデンサ
WO2008119694A1 (en) 2007-03-30 2008-10-09 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EP2170350B1 (en) 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
KR20200008045A (ko) * 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
MX346533B (es) 2011-02-25 2017-03-14 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター

Also Published As

Publication number Publication date
MX2013009760A (es) 2014-06-11
PH12013501726A1 (en) 2014-01-13
CA2827057A1 (en) 2012-08-30
CN103608343A (zh) 2014-02-26
NZ614787A (en) 2014-08-29
JP2014506602A (ja) 2014-03-17
SG192817A1 (en) 2013-09-30
EP3395812B1 (en) 2022-09-28
DK3395812T3 (da) 2022-11-28
CO6852066A2 (es) 2014-01-30
AU2012222146B2 (en) 2017-05-11
AU2012222146A1 (en) 2013-09-19
CL2013002436A1 (es) 2014-01-24
US9458136B2 (en) 2016-10-04
EA035989B1 (ru) 2020-09-09
US11560369B2 (en) 2023-01-24
EP3395812B8 (en) 2022-11-02
US20210380560A1 (en) 2021-12-09
EP2678330A1 (en) 2014-01-01
CA2827057C (en) 2022-06-07
EP3395812A1 (en) 2018-10-31
US20190308952A1 (en) 2019-10-10
US10183930B2 (en) 2019-01-22
US10981895B2 (en) 2021-04-20
MX346533B (es) 2017-03-14
EP4166552B1 (en) 2025-03-19
EP4166552A1 (en) 2023-04-19
IL227782A0 (en) 2013-09-30
US20140135345A1 (en) 2014-05-15
WO2012116276A1 (en) 2012-08-30
CN103608343B (zh) 2019-02-01
EA201391233A1 (ru) 2014-02-28
JP5945554B2 (ja) 2016-07-05
ES2932441T3 (es) 2023-01-19
BR112013021549A2 (pt) 2016-11-01
KR20140025353A (ko) 2014-03-04
MY165767A (en) 2018-04-23
KR102036932B1 (ko) 2019-10-25
ZA201306402B (en) 2022-03-30
BR112013021549B1 (pt) 2022-01-11
US20170144993A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
IL227782A (en) Crystalline forms and processes for making cannabinoid receptor modulators
IL230501A0 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and their use as a5c receptor modulators
SG11201401776WA (en) Nmda receptor modulators and uses thereof
EP2791132A4 (en) ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
ZA201305972B (en) Method for the preparation of biphephos
EP3385252B8 (en) Cannabinoid receptor modulators
SG10201501575VA (en) Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2620531A4 (en) APPARATUS FOR PRODUCING SINGLE CRYSTALS
SG11201400939YA (en) Process for the preparation of methoxymelonal
ZA201403736B (en) Process for the preparation of sterol derivatives
ZA201308942B (en) Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
IL232424A (en) Process for the preparation of 1-noble-4-phenylsulfonylprolinamide and intermediates
IL221184A (en) A process for preparing 1-alkylated tetrazole 5 is produced
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
PT2593423E (pt) Processo para a preparação de agentes de contraste
PL2702045T3 (pl) Nowy sposób sporządzania Etrawiryny
PT2390246T (pt) Processo para a preparação de aminaftona
ZA201403502B (en) Nicotinic receptor non-competitive modulators
PT2598504E (pt) Novo processo de fabrico de dimiracetam
HK1193088A (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
HK1192550A (en) Cannabinoid receptor modulators
AU2011904606A0 (en) Modulators of C3a receptors
HK1195310A (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
IL224304A (en) A process for making dichlorobulben

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed